Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

Cao, Jian-zhou; Wu, Wei; Pan, Jinfeng; Wang, Hongwei; Jiang, Junhui; Ma, Qi

doi:10.3389/fonc.2021.643413

Cited by 6 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are limited reports about the treatment of UC with PD-1 inhibitor therapy alone or combined with other chemotherapeutic drugs. A recent report demonstrated the partial response to sintilimab combined with nanoparticle albumin-boundpaclitaxel therapy for recurrent bladder UC and pelvic metastasis over an 11-month follow-up [8]. In the present report, our patient with recurrent and metastatic UC achieved sustained response after PD-1 inhibitor therapy combined with docetaxel therapy over 31 months.…”

Section: Discussionsupporting

confidence: 67%

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Ma¹,

Hong-yuan²,

Fang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have shown encouraging outcomes against Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer with mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H). However, there is as yet no clarity on the safety and efficacy of immunotherapy combined with chemotherapy in LS-associated urothelial carcinoma (UC). Here, we report a patient with recurrent and metastatic LS-associated UC who achieved sustained response to programmed death protein 1 (PD-1) inhibitor combined with chemotherapy over 31 months, during which the side effects of immunotherapy could be controlled and managed. Our findings indicate that the dMMR/MSI status and PD-1 expression in UC may have potential predictive value for the response to PD-1-targeted immunotherapy. Our case supports the inclusion of such combination and/or monotherapy for UC in clinical studies and using dMMR/MSI status and PD-1 expression as potential predictive biomarkers for assessment of the therapeutic response.

show abstract

Section: Discussionsupporting

confidence: 67%

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Ma¹,

Hong-yuan²,

Fang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Most patients experienced grade 1-2 AEs. Anemia was the most common, and it was caused mainly by tislelizumab, as in previous studies (Cao et al, 2021). Reactive capillary hemangioma is the most specific AE of camrelizumab, as in other published study (Chen et al, 2019).…”

Section: Discussionsupporting

confidence: 69%

“…Tislelizumab and toripalimab have resulted in encouraging outcomes for advanced UC in clinical trials (Ye et al, 2021;Sheng et al, 2022), and they were approved by the National Medical Products Administration for advanced UC. Camrelizumab and sintilimab have also shown beneficial effects in some cases (Cao et al, 2021;Ni et al, 2021;Wang et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

et al. 2022

View full text Add to dashboard Cite

Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC.Methods: We reviewed 118 patients treated with PD-1 inhibitors for advanced UC from July 2019 to October 2021 at Yantai Yuhuangding Hospital. Patient data were obtained from hospital records and telephone follow-ups. The safety and efficacy of PD-1 inhibitors were assessed by RESIST and Common Terminology Criteria for Adverse Events (version 4.0), respectively.Results: During a median follow-up period of 6 months, 112 patients (95%) experienced AEs; of these, 104 (88%) were grade 1–2 AEs, and 60 (51%) were grade 3–4 AEs. The most common AE was anemia, and no patients died as a result of treatment. A subanalysis according to treatment method (PD-1 inhibitor vs. PD-1 inhibitor plus chemotherapy) was performed. The incidence of grade 1–2 AEs was not different between the groups (85% vs. 94%), but combination therapy significantly increased grade 3–4 AEs (32% vs. 89%). Monotherapy and combination therapy also did not differ with regard to immune-related AEs of grades 1–2 (13% vs. 22%) or grades 3–4 (1% vs. 6%). In efficacy, complete response was not observed, but 33 patients (28%) had partial response, 30 (25%) had stable disease, and 47 had progressive disease (40%). The overall response and disease control rates were 28% and 53%, respectively. The preliminary efficacy of disease control was better with combination therapy versus monotherapy (78 vs. 43%).Conclusion: PD-1 inhibitors show promising tolerance and efficacy in advanced UC. PD-1 inhibitors combined with chemotherapy offered better disease control but had more grade 3–4 AEs. The clinical use of combination therapy warrants caution.

show abstract

“…We reported a case that a metastatic urothelial bladder carcinoma patient with FGFR3 mutations failed with multiple lines of standard treatments. After his case was discussed in our MDT meeting, Anlotinib combined with Sintilimab was recommended, and partial response (PR) was observed for more than 11 months (23). Another patient with bladder cancer had failed with platinum chemotherapy and multiple hepatic and pelvic metastases were found in his body.…”

Section: Discussionmentioning

confidence: 99%

Compliance with MDT recommendations is the key element for patients to benefit from MDT in complicated genitourinary tumors: a single-center data set

Huang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: This study aims to evaluate the applications and benefits of the multiple-disciplinary team (MDT) model in the clinical practices of complicated genitourinary tumors and to explore the importance of patients’ compliance with MDT recommendations. Methods: This was a descriptive study of 259 MDT consultations in our center over the past five years (2018-2022). All data recorded in the database were retrospectively analyzed, including clinical history, initial decisions, MDT decisions, actual treatments, and efficacy assessments. Results: A total of 259 consultations were performed on 222 patients with an average age of 65.21±12.87 years old (range,18 to 92 years old). Of the 259 consultations, 149 (57.5%) were for prostate cancer, 48 (18.5%) for kidney cancer, 24 (9.3%) for bladder cancer, 13 (5.0%) forupper tract urothelial cancer, 6 (2.3%) for testicular cancer, 2 (0.8%) for adrenal gland cancer, 6 (2.3%) for multiple primary tumors and 11 (4.2%) for other problems. Patients fully accepted the MDT recommendations in 201 consultations (77.6%); Partially accepted the MDT recommendations in 32 consultations (12.4%). The total rate of compliance was about 90.0% and 226 patients benefitted in the compliance group. Only 2 patients benefitted after MDT consultations in the noncompliance group. Compliance with MDT recommendations was found to be more beneficial for patients than the non-compliance group in our study (P＜0.001). Conclusion: Our findings suggest that MDT should be recommended for patients with complicated genitourinary cancers. Compliance with recommendations is the key element for patients benefitted from MDT consultations and we should focus on ways to enhance patients’ adherence.

show abstract

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

Cited by 6 publications

References 34 publications

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Compliance with MDT recommendations is the key element for patients to benefit from MDT in complicated genitourinary tumors: a single-center data set

Contact Info

Product

Resources

About